4.2 Durham-Humphrey, Kefauver-Harris & Product Information

4.2 Durham-Humphrey, Kefauver-Harris & Product Information

The modern practice of pharmacy is structured by two landmark mid-twentieth-century federal amendments to the FDCA: the Durham-Humphrey Amendment of 1951 and the Kefauver-Harris Drug Amendments of 1962. Together, these statutes established the modern prescription dispensing system, safety and efficacy standards, and consumer drug risk communication protocols. In addition, pharmacists must navigate complex FDA-mandated risk communication tools, including Package Inserts (PI), Patient Package Inserts (PPI), Medication Guides (MedGuides), Black Box Warnings, and Risk Evaluation and Mitigation Strategies (REMS).

---

1. The Durham-Humphrey Amendment of 1951

Prior to 1951, manufacturers determined whether their products were sold over-the-counter or upon prescription, leading to widespread confusion, unsafe self-medication, and divergent state enforcement. The Durham-Humphrey Amendment (Prescription Drug Amendment of 1951) amended Section 503(b) of the FDCA to resolve these issues:

┌─────────────────────────────────────────────────────────────────────────────┐
│                     DURHAM-HUMPHREY AMENDMENT OF 1951                       │
├─────────────────────────────────────────────────────────────────────────────┤
│ 1. Created Two Distinct Drug Classes:                                       │
│    • Prescription (Legend) Drugs: Unsafe for self-medication; requires      │
│      medical supervision. Must bear 'Rx only' or statutory legend.          │
│    • Over-the-Counter (OTC) Drugs: Safe and effective for lay self-use      │
│      when labeled with 'adequate directions for use' (Drug Facts label).    │
│                                                                             │
│ 2. Legalized Verbal (Oral) Prescriptions:                                   │
│    • Authorized pharmacists to receive oral prescription orders by phone    │
│      and promptly reduce them to writing.                                   │
│                                                                             │
│ 3. Legalized Prescription Refills:                                          │
│    • Authorized written and verbal refill authorizations from prescribers.  │
│                                                                             │
│ 4. Codified Pharmacist Dispensing Label Exemption (Section 503(b)(2)):      │
│    • Dispensed prescription vials are exempt from full manufacturer package │
│      insert labeling provided the pharmacy label meets statutory criteria.  │
└─────────────────────────────────────────────────────────────────────────────┘

Criteria for Prescription (Legend) Status

A drug must be dispensed pursuant to a prescription if it satisfies either standard:

1. Toxicity / Potential for Harm: Because of its toxicity, potential for harmful effects, method of use, or collateral measures necessary to its use, the drug is not safe for use except under the supervision of a practitioner licensed by law to administer such drug.
2. NDA Limitation: The drug is limited by an approved New Drug Application (NDA) to use under the professional supervision of a licensed practitioner.

The Federal Legend

Prescription drugs must bear the symbol "Rx only" or the historical federal legend: "Caution: Federal law prohibits dispensing without prescription." If a legend drug is dispensed without a valid prescription or without an authorized refill, the drug is misbranded as a matter of federal law.

---

2. The Kefauver-Harris Drug Amendments of 1962

In the late 1950s and early 1960s, thalidomide was widely marketed in Europe as a non-toxic sedative and morning sickness remedy. It was withheld from U.S. approval by FDA medical reviewer Dr. Frances Kelsey due to lack of peripheral neuropathy safety data. Shortly thereafter, thalidomide was discovered to cause catastrophic teratogenic birth defects (phocomelia—severe shortening or absence of limbs) in thousands of infants worldwide. In response, Congress enacted the Kefauver-Harris Drug Amendments of 1962 (Drug Efficacy Amendment).

Core Mandates of Kefauver-Harris

1. Pre-Market Proof of Efficacy: Manufacturers must prove not only that a drug is safe, but also that it is effective for its intended indications through "adequate and well-controlled clinical investigations" prior to FDA approval.
2. Retroactive Efficacy Review (DESI): Established the Drug Efficacy Study Implementation (DESI) program to evaluate the efficacy of all medications approved between 1938 and 1962 based on safety alone.
3. Current Good Manufacturing Practice (CGMP): Mandated that manufacturers comply with comprehensive quality control and manufacturing standards (21 CFR Parts 210/211) to ensure drug identity, strength, quality, and purity.
4. Prescription Drug Advertising Jurisdiction: Transferred regulatory oversight of prescription drug advertising from the Federal Trade Commission (FTC) to the FDA. (The FTC retains jurisdiction over non-prescription OTC drug advertising).
5. Informed Consent & Adverse Drug Event Reporting: Required clinical investigators to obtain informed consent from human trial participants and mandated post-marketing reporting of adverse drug events (MedWatch system / FAERS).

3. FDA Official Product Labeling: PI, PPI & MedGuides

Federal regulations mandate multiple tiers of product labeling designed for distinct audiences: healthcare practitioners and patient consumers.

┌─────────────────────────────────────────────────────────────────────────────┐
│                     FDA PRODUCT LABELING COMPARISON MATRIX                  │
├─────────────────────┬───────────────────────┬───────────────────────────────┤
│ Labeling Category   │ Primary Target        │ Mandatory Distribution Rules  │
├─────────────────────┼───────────────────────┼───────────────────────────────┤
│ Package Insert (PI) │ Healthcare Providers  │ Included with commercial bulk │
│                     │ (Physicians, PharmDs) │ stock bottles by manufacturer.│
├─────────────────────┼───────────────────────┼───────────────────────────────┤
│ Patient Package     │ Patient / Consumer    │ Required for Oral             │
│ Insert (PPI)        │                       │ Contraceptives & Estrogens.   │
│                     │                       │ Outpatient: Every fill.       │
│                     │                       │ Inpatient: 1st dose + q30d.   │
├─────────────────────┼───────────────────────┼───────────────────────────────┤
│ Medication Guide    │ Patient / Consumer    │ Required for drugs with       │
│ (MedGuide)          │                       │ serious public health risks   │
│                     │                       │ (NSAIDs, Opioids, SSRIs, etc.)│
│                     │                       │ Outpatient: Every fill.       │
└─────────────────────┴───────────────────────┴───────────────────────────────┘

1. Package Insert (PI) for Healthcare Professionals

The official Package Insert (PI) contains comprehensive scientific information required for safe and effective prescribing and dispensing. Under the FDA's Physician Labeling Rule (PLR), the PI features a standardized format: Highlights of Prescribing Information, Boxed Warning, Indications and Usage, Dosage and Administration, Contraindications, Warnings and Precautions, Adverse Reactions, Drug Interactions, and Use in Specific Populations.

Pregnancy and Lactation Labeling Rule (PLLR): In 2015, the FDA eliminated the historical pregnancy letter categories (A, B, C, D, X) for all prescription drugs. The PLLR requires narrative risk summaries under three subsections: 8.1 Pregnancy, 8.2 Lactation, and 8.3 Females and Males of Reproductive Potential.

2. Patient Package Inserts (PPI)

PPIs are FDA-approved informational leaflets written in lay language detailing clinical benefits, risks, and contraindications. Under 21 CFR § 310.501, PPIs are legally mandated for:

• Oral Contraceptive Drugs (combination and progestin-only).
• Estrogen-Containing Products (e.g., conjugated estrogens, estradiol tablets, patches, and vaginal creams).

Mandatory PPI Dispensing Rules

• Outpatient / Retail Setting: The pharmacist must dispense a PPI with EVERY dispensing (both the initial fill and every subsequent refill).
• Institutional / Inpatient Setting (Hospitals & LTCFs): The facility must provide the PPI prior to the administration of the first dose, and at least once every 30 days thereafter for as long as the therapy continues.
• Legal Consequence: Dispensing an estrogen or oral contraceptive without the required PPI constitutes misbranding under FDCA § 502.

3. Medication Guides (MedGuides) — 21 CFR Part 208

Medication Guides are FDA-approved paper handouts required for specific prescription drugs or biological products that pose a "serious and significant public health concern."

FDA Criteria for Mandating a MedGuide

A MedGuide is required if the FDA determines that:

1. Patient labeling could help prevent serious adverse effects;
2. The product has serious risks (relative to benefits) of which patients should be made aware to decide whether to use or continue using the medication; or
3. Patient adherence to directions for use is crucial to the drug's effectiveness.

Major Drug Classes Requiring MedGuides

MedGuide Dispensing Rules

Under federal law, a MedGuide must be provided by the dispenser whenever:

• The patient or patient's caregiver requests a MedGuide;
• The drug is dispensed in an outpatient setting (new prescription or refill) where the drug will be used by the patient without direct supervision by a healthcare professional;
• The drug is dispensed under a REMS program that mandates MedGuide distribution; or
• The MedGuide has been materially revised by the FDA.
• Failure to provide a required MedGuide renders the drug misbranded.

4. Black Box Warnings & REMS Programs

Black Box Warnings (Boxed Warnings)

A Black Box Warning is the FDA's most stringent safety warning placed on prescription drug labeling. Boxed warnings are prominently bordered in black at the beginning of the Package Insert to highlight:

• Adverse reactions so serious in proportion to the therapeutic benefit that they must be considered in assessing the risks and benefits of the drug;
• Serious adverse reactions that can be prevented or reduced in severity by appropriate use (e.g., patient selection, strict lab monitoring, dose adjustment);
• FDA restrictions on distribution or use.

Risk Evaluation and Mitigation Strategies (REMS)

Authorized under the Food and Drug Administration Amendments Act (FDAAA) of 2007, a REMS is a required risk-management program designed to ensure that the therapeutic benefits of a high-risk medication outweigh its known safety risks. While some REMS require only a Medication Guide or Communication Plan, the most critical programs incorporate Elements to Assure Safe Use (ETASU).

High-Yield REMS Programs on the MPJE

1. The iPLEDGE Program (Isotretinoin)

• Target Risk: Severe teratogenicity, spontaneous abortion, and severe congenital fetal malformations.
• Mandatory Registrants: Wholesalers, prescribers, pharmacies, and all patients (both patients who can become pregnant and patients who cannot become pregnant).
• Pregnancy Testing Protocol (Patients Who Can Become Pregnant):
  • Must have two (2) negative CLIA-certified pregnancy tests prior to initiating therapy (one screening test, followed by a confirmatory test performed during the first 5 days of the menstrual cycle).
  • Must have one (1) negative CLIA-certified pregnancy test each month prior to obtaining each subsequent prescription.
  • Must commit to using two (2) effective methods of birth control simultaneously or practice continuous complete abstinence.
• The 7-Day Dispensing Window: For patients who can become pregnant, the prescription must be dispensed within seven (7) days of the pregnancy test collection date. If not picked up within 7 days, the authorization expires, and a new pregnancy test must be completed.
• Window for Patients Who Cannot Become Pregnant: Must be dispensed within 30 days of the office visit date.
• Quantity Limits & Refills: Maximum of 30-day supply per prescription. NO refills are permitted on any isotretinoin prescription.
• Pharmacy Verification: The dispensing pharmacist must log into the online iPLEDGE system, verify that all patient criteria and prescriber authorizations are satisfied, and obtain a Risk Management Authorization (RMA) number before dispensing.

2. Clozapine REMS (Clozaril)

• Target Risk: Life-threatening severe neutropenia and agranulocytosis.
• Centralized Single Registry: All prescribers, pharmacies, and patients must be registered in the centralized Clozapine REMS registry.
• Monitoring Metric: Absolute Neutrophil Count (ANC) only. (Historical white blood cell [WBC] counts are no longer used independently).
• ANC Thresholds for Initiation:
  • General Population: ANC $\ge 1,500/\mu\text{L}$.
  • Benign Ethnic Neutropenia (BEN): ANC $\ge 1,000/\mu\text{L}$.
• Mandatory ANC Monitoring Schedule:
  • Months 1 to 6: Weekly ANC draws.
  • Months 6 to 12: Every 2 weeks.
  • After 12 Months: Every 4 weeks (monthly) for the duration of therapy.
• Pharmacy Verification: Pharmacist must verify that an ANC draw occurred within the appropriate monitoring interval and obtain an online Patient Dispense Authorization (PDA) from Clozapine REMS before dispensing.

3. TIRF REMS (Transmucosal Immediate-Release Fentanyl)

• Target Risk: Fatal respiratory depression from accidental exposure or inappropriate use in opioid-naive individuals.
• Approved Indication: Strictly indicated for the management of breakthrough pain in cancer patients who are already opioid tolerant.
• Opioid Tolerance Definition: Patients taking at least $60\text{ mg}$ oral morphine daily, $30\text{ mg}$ oral oxycodone daily, $8\text{ mg}$ oral hydromorphone daily, or an equianalgesic dose of another opioid for $\ge 1\text{ week}$.
• Enrollment: Requires prescriber, pharmacy, and patient enrollment; pharmacies must verify patient tolerance before dispensing.

4. TOUCH Prescribing Program (Natalizumab / Tysabri)

• Target Risk: Progressive Multifocal Leukoencephalopathy (PML), a rare, opportunistic, frequently fatal viral infection of the central nervous system.
• Enrollment & Checkpoints: Prescriber, pharmacy, infusion site, and patient must be enrolled; mandatory clinical assessments and periodic MRI evaluations prior to each infusion.

---

5. Exam Watch: High-Yield Scenarios & Traps

Clinical Scenarios

• Scenario A (Inpatient PPI Dispensing): A patient is admitted to an acute-care hospital on March 1 and started on oral conjugated estrogens (Premarin). The hospital pharmacy provides a PPI on March 1. The patient remains hospitalized for 45 days. The pharmacy does not provide another PPI. Legal Analysis: UNLAWFUL (Misbranding). In institutional settings, PPIs must be provided prior to the first dose and at least every 30 days thereafter (a second PPI was required on or before March 31).
• Scenario B (iPLEDGE Day 8 Dispensing): A 22-year-old female patient has a negative pregnancy test on Monday, August 1. On Tuesday, August 9 (Day 8), she presents to the pharmacy to pick up her isotretinoin. The pharmacist generates a label and dispenses the medication. Legal Analysis: UNLAWFUL. The 7-day dispensing window expired on Day 7 (August 8). The pharmacy cannot dispense the drug without a new pregnancy test and updated RMA.

High-Yield Labeling & REMS Traps

• ⚠️ Trap 1: Forgetting Refill PPI Requirements. Community pharmacists frequently forget that oral contraceptives and estrogen products require a PPI with every single refill, not just the initial fill.
• ⚠️ Trap 2: MedGuide vs. PPI Misclassification. PPIs are mandated for estrogens/oral contraceptives; MedGuides are mandated for broader drug classes (NSAIDs, SSRIs, opioids, DOACs). Both cause misbranding if omitted.
• ⚠️ Trap 3: Prescribing Limits on Isotretinoin. Isotretinoin can NEVER have refills, and the maximum quantity is strictly capped at a 30-day supply.